A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
2016-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of ponatinib in participants
with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure
of prior tyrosine kinase inhibitor (TKI) therapy.